Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 1/20 | 0.49 |
| ▸ | RPS6KA5 | O75582 | 2/20 | 0.46 |
| ▸ | CCNT1 | O60563 | 2/20 | 0.39 |
| ▸ | CDK2 | P24941 | 2/20 | 0.39 |
| ▸ | CDK9 | P50750 | 2/20 | 0.39 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.39 |
| ▸ | CDK7 | P50613 | 3/20 | 0.38 |
| ▸ | CCNH | P51946 | 3/20 | 0.38 |
| ▸ | MNAT1 | P51948 | 3/20 | 0.38 |
| ▸ | CCNK | O75909 | 2/20 | 0.38 |
| ▸ | CDK12 | Q9NYV4 | 2/20 | 0.38 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.38 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.38 |
| ▸ | SGK1 | O00141 | 1/20 | 0.38 |
| ▸ | CAMKK2 | Q96RR4 | 1/20 | 0.38 |
| ▸ | MAP3K14 | Q99558 | 1/20 | 0.37 |
| ▸ | BRAF | P15056 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15998701 | 0.89 | JAK2 (0.48) | JAK2CCNT1CDK2CDK9CCNA2 | |
| SCHEMBL15648351 | 0.78 | CDK2 (0.55) | RPS6KA5CCNT1CDK2CDK9CDK7 | |
| SCHEMBL19710201 | 0.77 | JAK2 (0.50) | JAK2BRAF | |
| SCHEMBL16152907 | 0.72 | HPGD (0.31) | — | |
| SCHEMBL25598658 | 0.69 | CCNT1 (0.60) | JAK2RPS6KA5CCNT1CDK2CDK9 | |
| SCHEMBL14327598 | 0.69 | JAK2 (0.38) | JAK2 | |
| SCHEMBL8942851 | 0.67 | JAK2 (0.65) | JAK2RPS6KA5CCNT1CDK2CDK9 | |
| SCHEMBL14712339 | 0.67 | JAK2 (0.49) | JAK2CCNT1CDK2CDK9CCNA2 | |
| SCHEMBL27787175 | 0.67 | JAK2 (0.51) | JAK2BRAF | |
| SCHEMBL8941748 | 0.66 | JAK2 (1.00) | JAK2CDK2SGK1CAMKK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8987454-B2 | Azaindoles useful as inhibitors of JAK and other protein kinases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2015-03-24 | — | — | US | disclosed |
| US-8987454-B2 | Azaindoles useful as inhibitors of JAK and other protein kinases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2015-03-24 | — | — | US | disclosed |
| US-20140249138-A1 | AZAINDOLES USEFUL AS INHIBITORS OF JAK AND OTHER PROTEIN KINASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-09-04 | — | — | US | disclosed |
| US-8722889-B2 | Azaindoles useful as inhibitors of JAK and other protein kinases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-05-13 | — | — | US | disclosed |
| US-8722889-B2 | Azaindoles useful as inhibitors of JAK and other protein kinases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-05-13 | — | — | US | disclosed |
| US-8501446-B2 | Azaindoles useful as inhibitors of JAK and other protein kinases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-08-06 | — | — | US | disclosed |
| US-20120258958-A1 | AZAINDOLES USEFUL AS INHIBITORS OF JAK AND OTHER PROTEIN KINASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-10-11 | — | — | US | disclosed |
| US-20120258958-A1 | AZAINDOLES USEFUL AS INHIBITORS OF JAK AND OTHER PROTEIN KINASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-10-11 | — | — | US | disclosed |
| US-8188281-B2 | Azaindoles useful as inhibitors of JAK and other protein kinases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-05-29 | — | — | US | disclosed |
| US-8188281-B2 | Azaindoles useful as inhibitors of JAK and other protein kinases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-05-29 | — | — | US | disclosed |
| US-20090176763-A1 | Azaindoles useful as inhibitors of JAK and other protein kinases | VERTEX PHARMACEUTICALS INCORPORATED | 2009-07-09 | — | — | US | disclosed |
| US-20090176763-A1 | Azaindoles useful as inhibitors of JAK and other protein kinases | VERTEX PHARMACEUTICALS INCORPORATED | 2009-07-09 | — | — | US | disclosed |
| US-7507826-B2 | Such as 3-(2-Methanesulfonyl-pyrimidin-4-yl)-5-pyridin-3-yl-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyridine; heart disease, diabetes, Alzheimer's disease, immunodeficiency disorders, inflammatory diseases, hypertension, allergic diseases, autoimmune diseases, destructive bone disorders | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2009-03-24 | — | — | US | disclosed |
| US-7507826-B2 | Such as 3-(2-Methanesulfonyl-pyrimidin-4-yl)-5-pyridin-3-yl-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyridine; heart disease, diabetes, Alzheimer's disease, immunodeficiency disorders, inflammatory diseases, hypertension, allergic diseases, autoimmune diseases, destructive bone disorders | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2009-03-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120258958-A1 | AZAINDOLES USEFUL AS INHIBITORS OF JAK AND OTHER PROTEIN KINASES | JAK3, JAK2, JAK1 | JAK2 2/4885RPS6KA5 174/4885CCNT1 878/4885 |
| US-20090176763-A1 | Azaindoles useful as inhibitors of JAK and other protein kinases | JAK3, JAK2, JAK1 | JAK2 2/4885RPS6KA5 174/4885CCNT1 878/4885 |
| US-20140249138-A1 | AZAINDOLES USEFUL AS INHIBITORS OF JAK AND OTHER PROTEIN KINASES | JAK3, JAK2, JAK1 | JAK2 2/4885RPS6KA5 174/4885CCNT1 878/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.